Immunotherapy for nonsmall-cell lung cancer

  • Astrid Belalcazar
  • Luis E. Raez
  • Edgardo S. Santos
short review

Abstract

Systemic chemotherapy for nonsmall-cell lung cancer (NSCLC) has reached a plateau in effectiveness for several years and certainly biological therapy (approved antiangiogenic agents and tyrosine kinase inhibitors) has slightly improved survival; however, the mortality of NSCLC is very high and survival of metastatic disease is less than 2 years. Therefore, new approaches are required to improve current outcomes. Active-specific immunotherapy is an area of oncology that is rapidly expanding and delivering promising results such as asymptomatic prostate cancer with the use of sipuleucel-T. In the field of lung cancer, there are multiple vaccines focused on creating specific antitumor activity in NSCLC. Whole-cell vaccines like belagenpumatucel-L and antigen-specific vaccines like L-BLP25, TG4010, EGF vaccine and MAGE-A3 vaccines are undergoing phase III clinical trials after having demonstrated encouraging results in previous phase II trials with minimum toxicity. Hopefully, positive results will be revealed in the next few years, giving our lung cancer patients a new and more personalized therapy with better quality of life. The short review is indented to give an overview of the current data in the main studies of active immunotherapy for NSCLC.

Keywords

Immunotherapy Nonsmall-cell lung cancer Antigens Vaccines Stimuvax BLP25 MAGE-A3 

References

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2(11):e1129.CrossRefPubMedGoogle Scholar
  3. 3.
    Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of nonsmall cell lung cancer. Therapy. 2011;8(1):43–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Gross S, Walden P. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer? Immunol Lett. 2008;116(1):7–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-b1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86(9):1712–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Clinicaltrials.gov: Phase III Lucanix vaccine therapy in advanced non-small-cell lung cancer (NSCLC) following front-line chemotherapy (STOP). www.clinicaltrials.gov/ct2/show/NCT00676507. Accessed 1 Feb. 2012.Google Scholar
  9. 9.
    Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25(1):131–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;s25:7554 (Meeting Abstracts).Google Scholar
  11. 11.
    Clinicaltrials.gov: GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small-cell lung cancer.http:\\www.clinicaltrials.gov/ct2/show/NCT00480025. Accessed 1 Feb. 2012.
  12. 12.
    Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small-cell lung cancer cells. Mol. Cancer Ther. 2011;10(5):806–16.CrossRefPubMedGoogle Scholar
  13. 13.
    Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23(27):6674–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thor Oncol. 2007;2(8):s332–3.CrossRefGoogle Scholar
  15. 15.
    Butts C, Murray RN, Smith CJ, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010;11(6):391–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Clinicaltrials.gov: Cancer vaccine study for unresectable stage III non-small-cell lung cancer.http:\\www.clinicaltrials.gov/ct2/show/NCT00409188. Accessed 1 Feb 2012.
  17. 17.
    Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5(8):690–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3(7):735–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Acres B, Quoix E, Ramlau R, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol. 2009;s27:3027 (Meeting Abstracts).Google Scholar
  20. 20.
    Clinicaltrials.gov: Immunotherapy with TG4010 in patients with advanced non-small-cell lung cancerhttp://clinicaltrials.gov/ct2/show/NCT01383148. Accessed 1 Feb 2012.
  21. 21.
    Rodriguez G, Albisa A, Viña L, et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Int Biopharm. 2008;21(10):36–42.Google Scholar
  22. 22.
    Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of human recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998;9(4):431–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Garcia B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14(3):840–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(9):1452–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  • Astrid Belalcazar
    • 1
  • Luis E. Raez
    • 2
    • 3
  • Edgardo S. Santos
    • 4
  1. 1.University of Tennessee Health Science CenterMemphisUSA
  2. 2.Memorial Cancer InstituteMemorial Health Care SystemHollywoodUSA
  3. 3.Herbert Wertheim College of MedicineFlorida International UniversityPembroke PinesUSA
  4. 4.Sylvester Comprehensive Cancer CenterUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations